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SPIN TRAPPING PHARMACEUTICAL
COMPOSITIONS AND METHODS FOR USE
THEREOF

term memory. The precise mechanisms of functional

This application is a continuation of Ser. No. 08/969,
344, ?led on Nov. 28,1997 now US. Pat. No. 6,002,001,
Which is a continuation of Ser. No. 08/167,900, ?led Jul. 29,
1994, abandoned on Dec. 2, 1997, Which is a continuation
in-part of Ser. No. 08/212,800, ?led Mar. 15, 1994, now US.
Pat. No. 5,622,994, Which is a continuation of Ser. No.

changes as a result of aging, or other diseases associated

With aging, have not generally been agreed upon, including
several mechanisms for the generation of oxidiZed material
in the brain. A marked reduction in certain neurotransmitter
receptor systems has been associated With increased oxida
tion of proteins. For example, decreases in muscarinic
receptors and other cholinergic systems have been charac
10

08/052,870, ?led Apr. 23, 1993, abandoned on Mar. 22,

brain proteins. It has also been hypothesiZed that aging is
associated With multiple minor periods of ischemia (multi

1994, Which is a continuation of Ser. No. 07/716,952, ?led

Jun. 18, 1991, abandoned on Apr. 26, 1993.
BACKGROUND OF THE INVENTION

infarct conditions or transient ischemia attacks) Which, over
15

The present invention is a method and compositions

functions and disease conditions arising from oxidative

damage.
20

system. The data presented in US. Ser. No. 07/589,177
abandoned on Mar. 5, 1993, Was the ?rst report of substan
tial investigations in Which alterations in the oxidiZed pro
30

reperfusion damage. The most likely sites for production of
such radicals as the superoxide (O_2) and hydroxyl (OH—)
species, and the precursor oxygen species, H2O2 are the
mitochondrial respiratory chain speci?c enZymes and the

sequences catalyZed by cyclooxygenase and lipoxygenase.
many compounds (e.g., catecholamines). Ischemia appears
oxidation of polyenoic free fatty acids, release and reuptake

eral neuropathy and traumatic nerve damage, as Well as
40

interactions, energy failure, and/or calcium in?ux during the
45

Although free radical formation has been postulated to be
a likely cause of ischemic damage, it Was dif?cult to directly
demonstrate that such formation occurs and/or that it Was

Cell. Biol. 5, 167—172 (1985). Phenyl butyl nitrone (PBN)
has been used in a number of these in vitro research studies

using spin trapping to look for free radicals, but until
55

the proposition that it could be useful in vivo, particularly
With respect to treatment of tissue damage in the central
nervous system. In vivo, the drug must be able to both cross
60

In US. Ser. No. 07/589,177, abandoned on Mar. 5, 1993,
the use of PBN and related compounds, as Well as 5,5

dimethyl pyrroline N-oxide (DMPO) and ot-(4-pyridinyl-1
oxide)-N-tert-butylnitrone (POBN), for treatment of aging
system function have generally been associated With the loss
of cells, a Widening of lateral ventricles and de?cits in short

lar hemorrhage and associated vasospasm, spinal cord
trauma, vascular headaches, and neuroanesthesia adjunct.
It is another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,
Which are useful in treating damage in vivo resulting from
peripheral nervous system diseases, including diabetic
peripheral neuropathy and traumatic nerve damage.
It is still another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,
Which are useful in preventing or reversing free radical

the blood brain barrier and act in a manner Which reduces

Was described. Age related changes in central nervous

bitus ulcers, and ischemic boWel disease.
It is therefore an object of the present invention to provide
spin-trapping compositions and methods for use thereof
Which are useful in preventing or reversing ischemic damage
in vivo, in the CNS, resulting from diseases such as stroke,

aging, Parkinsonism, concussion, Berry aneurysm, ventricu

suf?ciently pronounced to overWhelm the antioxidative
defense of the tissue, as revieWed by Curran, et al., Mol.

tissue damage during or folloWing ischemia.

peripheral organ diseases. Examples of peripheral organ
diseases include atherosclerosis, pulmonary ?brosis,

pancreatitis, angioplasty, multiple organ failure, burns, decu

recirculation, When the O2 supply is restored, they represent
metabolic cascades triggered by agonist-receptor

demonstrated by the data in US. Ser. No. 07/422,651, now
US. Pat. No. 5,025,032, there has been no data to support

tem (CNS) diseases besides stroke and aging, including
Parkinsonism, trauma, vascular headaches, cerebral palsy,
diabetic neuropathy,and neuroanesthesia adjunct, as Well as
peripheral nervous system diseases such as diabetic periph

to favor a spurt of free-radical formation, resulting in

insult.

tein burden of the central nervous system Was manipulated
and correlated With a functional outcome on the part of the
animal. There are a number of other disorders and diseases
Which have noW been postulated to be associated With

oxidation of proteins, including many central nervous sys
35

HoWever, radicals are also formed during autoxidation of

of catecholamines, and oxidation of hypoxanthine by xan
thine oxidase. Despite these events occurring during

the level of oxidiZed protein in tissue gives rise to the
possibility that age related dysfunctions in the central ner
vous system may be associated With the build-up of oxidiZed
proteins and oxidiZed macromolecules Within neurons
throughout the central nervous system. The hypothesis is
that cells Which have a buildup of oxidiZed protein are less
functional and less able to maintain the speci?ed role of
those cells in that particular area of the central nervous

because of the necessity for complete integrity of all regions
in order to have proper functioning.
Free radicals have been postulated to be mediators of

a period of time, may give rise to the production of oxidiZed

protein.
The demonstration in a variety of systems, both neural
and nonneural, that there is an age related enhancement of

containing spin trapping agents for the treatment of dys
Oxygenated tissue suffers damage, in many cases perma
nent damage, if it becomes ischemic and is then reperfused.
Brain appears to be highly susceptible to ischemia/
reperfusion injury. Certain areas of the brain, for example,
the hippocampus and spinal cord, are more susceptible than
other regions of the brain. As a result, ischemia/reperfusion
injury to brain may have a multiplicative effect simply

teriZed as they relate to alterations in functions in AlZhe
imers disease. It is noW knoWn that the processes of aging
and AlZheimer’s disease are associated With oxidation of

65

damage in vivo resulting from injury, infection and
in?ammation, especially peripheral organ diseases such as
chronic obstructive pulmonary disease (COPD), atheroscle
rosis (both diabetic and spontaneous), pulmonary ?brosis
due to anti-cancer treatment, drug treatment, pancreatitis,
angioplasty, multi-organ failure folloWing trauma, burns
(chemical, thermal, and radiation), the progressive loss of
myocardial cells leading to cardiac failure as a result of

age-related oxidation, and ischemic boWel disease.
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It is another object of the present invention to provide
spin-trapping compositions for use in the process of organ

The term alkaryl refers to an alkyl group that has an aryl
substituent.

transplantation and preservation.

The term halo (alkyl or alkenyl) refers to an alkyl or
alkenyl group in Which at least one of the hydrogens in the
group has been replaced With a halogen atom. The term

It is a further object of the present invention to treat
disorders not associated With oxidation, such as undesirable
HDL/LDL ratios, as Well as the treatment of damage arising

haloalkyl speci?cally includes tri?uoromethyl.

from exposure to cytotoxic compounds and radiation.

The term aralkyl refers to an aryl group With an alkyl
substituent.

SUMMARY OF THE INVENTION

Spin trapping compounds in general have noW been
discovered to be effective in treating a variety of disorders,
including disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a Wide

1O

The term pharmaceutically active derivative refers to any

compound that upon administration to the recipient, is

capable of providing directly or indirectly, the compounds
disclosed herein.
15

variety of etiologies.

The term alkaryl refers to an alkyl group that has an aryl
substituent.
The term nontoxic refers to a compound that has a

Spin trapping compounds as referred to herein are mol
ecules that (1) have an unpaired electron; (2) form a stable
compound or complex With a free radical; and (3) are

therapeutic index of at least three.

nontoxic, i.e., have a therapeutic index (margin of safety;

compositions that contain spin trapping compounds or phar

ECSO/LCSO) of 3 or more.

maceutically acceptable derivatives or salts thereof for use
in medical therapy, for example for the treatment or pro

The invention disclosed herein includes pharmaceutical

The spin traps provide a unique signal that can be mea

sured by electron spin spectroscopy (ESR) When it binds to
a free radical. For example, the oxidation of brain tissue
involves a free radical intermediate. Brain tissue that has
been treated With PBN has been monitored by ESR. As a free
radical on a lipid or protein is generated, PBN traps the
radical and forms a covalently bound product With the

25

variety of etiologies.
The invention also includes the use of spin trapping
agents and pharmaceutically acceptable derivatives or salts

material, Which has a characteristically unique ESR signal.
The PBN-(lipid or protein) has then been isolated and

thereof in the manufacture of a medicament for treatment or

identi?ed.

AWide range of spin trapping compounds are disclosed in
detail herein. Other spin traps that meet the above three
requirements are knoWn to those of skill in the art of organic
and medicinal chemistry. An essential criteria for the selec
tion of the spin trap is that it actively trap free radicals
Without cytotoxicity, and that in the applications Where

phylaxis of disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a Wide

prophylaxis of disorders such as those arising from
ischemia, infection, in?ammation, exposure to radiation or

cytotoxic compounds, not just of the central and peripheral
35

nervous systems but of peripheral organ disease having a

Wide variety of etiologies.
It has noW been discovered that spin-trapping agents are

access to the CNS is required for efficacy, that the com

generally useful in preventing or treating symptoms associ

pounds pass through the blood brain barrier.
Many different disorders can be treated using these
compounds, including diseases or disorders of the central
and peripheral nervous systems, and disorders arising from
ischemia, infection, in?ammation, oxidation from exposure

ated With a very Wide range of disorders of the central and
peripheral nervous system, as Well as peripheral organ

naturally occurring processes such as aging.

(chemotherapeutic compounds, in most instances).
Useful Spin-trapping Compounds.

disfunction and disease, including not just aging, trauma,
ischemia but disorders as disparate as undesirable ratios of

lipoproteins, ulcerative colitis, and damage arising from

to radiation or cytotoxic compounds, as Well as due to 45 exposure to radiation and cytotoxic compounds

DETAILED DESCRIPTION OF THE
INVENTION

PBN and derivatives thereof.

The preferred spin-trapping compounds are phenyl

The term alkyl, as used herein, unless otherWise speci?ed,
refers to a saturated straight, branched, or cyclic hydrocar

N-tert-butylnitrone, also referred to as ot-phenyl t-butyl
nitrone (PBN), and derivatives thereof of the formula:

bon of C1 to C10, and speci?cally includes methyl, ethyl,

propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl,
pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl,
cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3
dimethylbutyl, and cyclohexyl.

55

The term alkenyl, as referred to herein, and unless oth

erWise speci?ed, refers to a straight, branched, or cyclic (in
the case of C5_6) hydrocarbon of C2 to C10 With at least one

Wherein:

double bond.
The term aryl, as used herein, and unless otherWise
speci?ed, refers to phenyl or substituted phenyl, Wherein the
substituent is halo or loWer alkyl.
The term halo, as used herein, includes ?uoro, chloro,

bromo, and iodo.
The term aralkyl refers to an aryl group With an alkyl
substituent.

X is phenyl, imidaZolyl, phenothiaZinyl or
R2

65

3“
n=1—5, preferably 1—3;
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speci?cally including
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CH3

wherein R3=independently R2 (that can vary Within the
molecule) or H;

CH3

/

T

T

O
DMPO dimer

O

CH3
O

O—N

and R4 to R9 are independently R2, H or

O—l|:—C

/ \N/
I

CH3

/ \
_e.\R,

CH3

CH3

0

DMPO covalently bound to TEMPO

Other spin-trapping agents can also be used, such as

5,5-dimethyl pyrroline N-oXide (DMPO), ot-(4-pyridyl

1-oXide)-N-tert-butylnitrone (POBN), 3,3,5,5-tetramethyl
1 -pyrroline N-oXide, and 2,4,4,6-tri-tert
butylnitrosobenZene (BNB), and spin-trapping derivatives

PBN covalently bound to DMPO
3O

POBN and Derivatives Thereof.

The general formula for POBN is:

thereof. Many compounds are commercially available or can

be synthesiZed using methods knoWn to those skilled in the
art. ot-phenyl-N-phenylnitrone compounds for use as topical
antiin?ammatories are described by US. Pat. No. 4,224,340
to Campbell, et al., the teachings of Which are incorporated
herein.

35

0.

Wherein m = O to 4

DMPO and Derivatives Thereof

The general formula for DMPO, and speci?c derivatives
are:

A

B

45

/
N+

TEMPO and Derivatives Thereof.

|

2,2,6,6-Tetramethyl piperidinooXy (TEMPO) is a nitroX
ide organic free radical trap. The synthesis and chemistry of

0

nitroXide free radicals is referenced by Galfnley, B. J ., pp.

184—238 in Spin Labeling in Pharmacology Berliner, L. H.,
(Academic Press, NY, NY. 1976), the teachings of Which are
wherein A and B are independently —R2, —CH2OH,

incorporated herein. TEMPO and several derivatives thereof

—CH2OW, or

can be purchased from Aldrich Chemical Co., as can many
_

m‘

R2

_

55

other spin traps such as PBN, DMPO, and POBN and some
of their derivatives.
As discussed above, the important criteria for these com

pounds is that they must trap free radicals, especially
hydroXy and superoXide radicals, While remaining non-toXic
to normal cells. In those applications Where the compound
must reach the brain and other parts of the CNS, the
compound must also be loW molecular Weight to pass
through the blood brain barrier. In some applications, the

n is an integer from 1 to 5; and

Wis

higher molecular Weight dimers and polymers of the spin
trap may have advantages.

Conjugates and Polymers of Spin Trapping Compounds.
65

In another embodiment, spin trapping compounds are
covalently attached to knoWn pharmaceutical agents, by
methods knoWn to those skilled in the art. Examples of

US 6,403,627 B1
9
useful compounds include spin traps covalently bound to

antiin?ammatories, neuroactive compounds, antioxidants,
or calcium channel blockers. Examples as illustrated include

conjugates of acetaminophen, dopamine (or DOPA), vitamin
E, and nifediphene.

T

CH3—C—I|\I

OH ACETAMINOPHEN

H

T T CH3
:N
O

II

H

|

CH3

CH3

CH3—C—N

o
O

/ \
3»8“_
R

20

C

| | |
| |
C=N—C—CH2—C—N
l
CH3

OH

25

NO;

I
MeOC

l
N

NIFEDIPHENYL PBN
COMe

H—C

||

35

T—O

nicardipine, nifedipine, nitrendipine, diltriaZam and ?una
raZine; cardiac glycosides such as digitalis and analogues
thereof; adenergic antagonists such as propranalol; metal

CH3—C—CH3
CH3

T T

chelators such as desferal; modi?ed steroids such as laZ

T T CH3

CH3—C—N

o

C=N

aroids; antiin?ammatories such as prednisone; nonsteroidal
antiin?ammatories such as acetaminophen, ibuprofen, and

CH3

indomethacin; antioxidants such as vitamin E; and neuro

CH3

active compounds such as L-DOPA. The optimal position to
45

HO

Other drugs that can be covalently bound to the spin traps
include calcium channel blockers such as nimodipine,

CH2—CH2—NH2

DOPAMINE

bind the spin trap to the pharmaceutical agent is easily
determined using knoWn information on structure activity

relationships and bulk tolerance of the pharmaceutical agent.
In some cases spacers Will be required betWeen the spin-trap

HO

and the conjugated compound in order to preserve maximum

PII O
HO

activity.

CH2—C—C—OH

Spin traps can also be attached to antibodies or ligands for
speci?c receptors (such as certain hormones, enZymes, or

DOPA

NH2

even speci?c sugars or carbohydrates) Which are used to

HO

55
Derivatives of DOPA

—
\

R

3%“ /

T T CH3
CH2—C=N

CH3

CH3

“target” or otherWise concentrate the spin trapping com
pound. Depending on the structure of the spin trap, as Well
as the biologically active compound, it may be necessary to
insert a spacer betWeen the spin trap and the biologically

active compound.
Indications that the compositions are useful in treating.
The spin trap or free-radical scavenger compositions are
useful in treating a variety of dysfunctions or disorders

characteriZed by oxidiZed proteins or lipids in the tissues,
cells, or associated ?uids (such as the blood). Oxidation of
cytosolic protein has been demonstrated to occur in a Wide

variety of pathological conditions.
Accordingly, compounds Which have as their fundamental
mechanism of action the interference of production of

US 6,403,627 B1
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12

oxidized protein are useful in the treatment of a Wide variety

mediated oxidation. Dopamine can be oxidiZed to the neu

of diseases having What appears at ?rst glance to be Widely

rotoxin 6-OH dopamine Within the neuron. This neurotoxin
is activated by a second oxidation. Both of these reactions

dissimilar etiologies, because the fundamental cause of the

condition is oxidation of protein, nucleic acids, or lipids.

are thought to occur as a result of oxygen free radical

Disorders are generally divided into disorders of the

production and attack on the dopamine, a naturally occur

central and peripheral nervous’system and disorders of the

ring neurotransmitter. These oxygen radical mediated oxi

peripheral organs.

dations are thought to occur at a relatively sloW rate and to

Disorders of the CNS include stroke, aging,
Parkinsonism, concussion, aneurysm, ventricular hemor

be responsible for the progressive loss of motor function in
Parkinsonism and related conditions. Based upon the dem

rhage and associated vasospasm, migraine and other vascu

10

onstration that chronic administration of PBN can decrease

lar headaches, spinal cord trauma, diabetic retinopathy, and

the progressive oxidation that occurs folloWing a stroke, it is

neuroanesthesia adjunct. Disorders of the peripheral nervous

believed that PBN and other spin-trapping compounds Will
be effective in limiting the production of the neurotoxic

system include diabetic peripheral neuropathy and traumatic

dopamine oxidation products.

nerve damage.

Peripheral organ disease includes atherosclerosis (both
diabetic and spontaneous), chronic obstructive pulmonary
disease (COPD), pancreatitis, pulmonary ?brosis due to

15

chemotherapeutic agents, angioplasty, trauma, burns,

interruption of brain and spinal cord microcirculation, pro
ducing localiZed ischemia. This interruption in blood flow

ischemic boWel disease, Wounds, ulcers and bed sores,

lupus, ulcerative colitis, organ transplantation, renal
hypertension, overexertion of skeletal muscle, and epistaxis

Concussion
The majority of the research literature indicates that
concussion produces the bulk of its long term effects via

20

can be the result of the initial trauma and shearing of
capillaries or the consequence of the brain edema and

(pulmonary bleeding).

compression of the blood vessels. In any event, spin trapping

Other conditions associated With excessive oxidation of
proteins or lipids that can be treated include undesirable or

compounds are of therapeutic value as they have been
demonstrated to be in models of stroke.

altered oxidation of loW density lipoprotein, and dysfunction
from exposure to radiation, including x-ray, ultraviolet,
gamma and beta radiation, and cytotoxic compounds,
including those used for chemotherapy for cancer and viral
infections.
Treatment of Central Nervous System Diseases
Stroke
Multiple in vitro studies, as Well as the in vivo data

25

Berry Aneurysm and other types of aneurysm
This vascular problem results in bleeding on the brain and
presents as a serious and chronic headache or other neuro

30

logic symptom. The condition is ultimately treated by sur
gical repair of the vessel that has developed a Weak Wall.
HoWever, this condition often results in hemorrhage and
neural damage due to the bleeding. In addition, the presence
of blood on the outside of the vessel sensitiZes the vessels to
spasm and increases the risk of a stroke, as is also true in
concussion and other traumatic conditions. In addition to the

presented in US. Ser. No. 07/589,177 abandoned on Mar. 5,

1993, and US. Ser. No. 07/422,651 now US. Pat. No.
5,025,023, have demonstrated that there are a series of 35 radicals generated by spasm and stroke, the iron or other

biochemical changes that result in the production of free
radicals folloWing ischemia. PBN and other spin-trapping
compounds can covalently bind to these radicals and prevent
the peroxidation of cellular proteins and fatty acids. The
consequence of the trapping of these carbon-centered and
oxygen-centered radicals is the termination of the propaga
tion phase of free radical production Within the neuron. This
interruption of free radical production can decrease the
mortality and morbidity seen in strokes.

Aging

metal catalyZed generation of oxygen free radicals, similar
to What has been proposed for ischemia and concussion, also
represents a second source of free radicals.

Ventricular Hemorrhage and Associated Vasospasm
40

45

Aging has been demonstrated to be associated With the

production of abnormally high levels of oxidiZed proteins.
The consequence of this increased level of protein oxidation
is an abnormally loW level of critical enZymes in the affected
cells. While not all cells have been evaluated, it appears
from the in vivo data presented in US. Ser. No. 07/589,
177abandoned on Mar. 5, 1993, and US. Ser. No. 07/422,
651, now US. Pat. No. 5,025,032, and reports of in vitro

studies, that most, if not all, cells in the body Will undergo
abnormally high levels of protein oxidation. Decreases in
antioxidant systems and abnormally loW levels of mitochon
drial function have been described. The protein oxidation is
thought to arise from oxygen free radicals, largely generated
via a metal catalyZed reaction Within the cell. Studies have
noW been conducted that daily administration of a free

The same biochemical and physiological conditions as

described for Berry Aneurysm and their management by
spin trapping compounds Will apply for these conditions.
Migraine and other Vascular Headaches
Migraines are thought to arise in part from large vessel
vasodilation and compression of the microcirculation of the
cortex. This is another form of ischemia/reperfusion injury.
While spin-trapping compounds Will not prevent the initial
occurrence of these vascular headaches, they limit the extent
or frequency by trapping the free radicals that are generated

during the ischemia phase.
Spinal Cord Trauma
Spinal cord trauma involves the interruption of the normal
vascular supply due to shearing forces at the time of the
initial trauma and as a result of the subsequent edema of the
55

tissue. In addition, the hemorrhage that often accompanies
such trauma Will also generate vasospasm and directly

generated oxygen free radicals. Spin trapping compounds
limit this process and terminate the intracellular cascade of
60

radical spin trapping compound, PBN, for fourteen days

lipid and protein oxidation.
Neuroanesthesia Adjunct
Several procedures involve resection of brain tissue Which
Will result in hemorrhage in the immediate area. Other

completely reverses this process. Not only is the level of

protein oxidation decreased, but the abnormally loW level of

surgical procedures may be associated With increased risk of

enZyme activity is restored to normal.
Parkinsonism

cerebral blood flow interruption, either as a natural conse
65

quence of the procedure, e.g., cardiac surgery or heart

Research has indicated that one of the principle sources of

transplantation, or due to the unexpected interruption of

dopaminergic damage to the striatum is via free radical

110W, e.g., hemorrhage, clot folloWing angioplasty, cardiac
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arrest during surgery. In all of these conditions, spin
trapping compounds Will limit free radical mediated
damage, and Will limit the development of antigenic reac

TABLE 1-continued
Testing of antioxidation activity of PBN

tions or other changes in the vascular endothelium that Will
increase the risk of the development of a reaclusive injury.

control +

Test

Reduction in free radical mediated damage limits antigen/

sample

PBS

(nM/ml)

% inhibition"

antibody mediated tissue damage.
Peripheral Nervous System Diseases

NP133 LDL
NP135 LDL

0.54
0.33

0.28
0.11

48.1
66.7

Diabetics are Well knoWn for their tendencies to develop

peripheral neuropathies and progressively lose sensation in

10 *The actual percent inhibition in the presence of PBN is greater than the

measured value due to interference in the assay by the PBN.

limbs. In addition, diabetics have a higher risk to develop
atherosclerosis, Which may affect microvascular function.

Chronic Obstructive Pulmonary Disease (COPD)
COPD has been demonstrated to involve the attack of

One of the most frequently seen biochemical consequences

of diabetes is excessive glycation of proteins. It is believed
that folloWing glycation, there is a burst of protein oxidation
that is mediated by oxygen free radicals. It is thought that
this process of excessive glycation is critical in the devel

15

opment of damage to neurons and axons in the diabetic.

Since spin trapping compounds are quite effective in limit
ing intracellular free radical mediated damage, such com
pounds can be used in the chronic management of diabetic
neuropathies and other long term adverse consequences of
diabetes.
Traumatic Nerve Damage
Crushing injury to peripheral nerves, as in the hands,
arms, and legs, involves interruption of blood ?oW

20

Pancreatitis is believed to be the result of ischemic or
25

chemically derived peroxidation of pancreatic parenchyma.
Alcoholic pancreatitis is probably due to the direct effects of
the ethanol radical and the indirect vascular effects of
acetaldehyde mediated direct damage to proteins and indi
rect damage via catecholamine release and mitochondrial

(ischemia) and edema. Effective and prompt repair is depen
30

metabolism. There is currently no treatment for acute pan

creatitis. If the condition does not abate, it is generally
regarded as fatal in the severe form. Spin-trapping agents
can be used to mediate the acute reaction, alloWing the

that occurs as the tissue outgroWs the vascular supply.

Spin-trapping compounds can be used to provide greater
tolerance of partial hypoxia as vascular supply groWs to
reach the healing tissue. In addition, the same ischemia/
hypoxia protection that occurs in the non-vascular tissue
may also enhance the groWth of the endothelia as the

pathology, respectively. An alternative approach is to pro
vide to the pulmonary tissue, either via the pulmonary
vascular supply or via the airWay, radical spin-trapping
compounds Which Will limit the peroxidation of pulmonary
tissue and the consequent loss of alveolar tissue.
Pancreatitis

dent on the re-establishment of an effective oxygen and

nutrient supply. Often recovering tissue tends to outgroW its
blood supply and is restricted in recovery by the ischemia

interstitial alveolar macrophages on pulmonary tissue. Ani
mal models of this clinical condition have demonstrated that
increases or decreases in superoxide dismutase activity in
the lung can result in decreases or increases in pulmonary

patient time to recover.
35

Angioplasty
In the process of re-expanding or laser removal of

atheroma, there are periods of ischemia and reperfusion of
the vessel or energy mediated production of free radicals.

revasculariZation process occurs.

Peripheral Organ Diseases
Atherosclerosis (both diabetic and spontaneous

40

Diabetic atherosclerosis involves the abnormal and exces

and may also remove or damage the natural relaxant systems

sive glycation of protein in the vascular Wall. As discussed
above for diabetic neuropathy, this involves oxygen radical

that locally control the vascular tone. If uncontrolled, such
changes are likely to result in an increased risk of

production and consequent further damage to cytosolic
proteins. Spin-trapping compounds Will prevent this abnor
mal processing of cellular protein and other cellular con
stituents. In vitro studies have been conducted that demon
strate that PBN inhibits or reduces oxidation of loW density

lipoprotein in plasma. Plasma samples Were tested for oxi
dation of lipid measured using thiobarbioturic acid reactive
substance (TBAR, nM) and % inhibition of oxidation calcu
lated. Phosphate buffered saline (PBS) Was added to
controls, 0.1 mM PBN Was added to test samples, and the
controls and sealed samples incubated at 4° C. for seven
Weeks.
The results are shoWn in Table 1.

Recent studies have demonstrated that during this period,
superoxide and nitric oxide are produced. These products
have been demonstrated to further damage the endothelium

50

re-occlusion of the same vessel. Spin-trapping compounds
can prevent the generation of the oxy-radical cascade and
thereby reduce the likelihood of reocclusion folloWing
angioplasty. In the diabetic, there is also an increased risk of
cutaneous alteration associated With vascular dysfunction
and poor perfusion of the dermis.

Multi-organ failure folloWing trauma
A characteristic problem folloWing extreme trauma is the

development in the patient of a negative nitrogen balance,

poor protein synthetic capacity, pulmonary dysfunction, and
55

abnormal cytokine production. Tumor necrosis factor (TNF)
is excessively elevated during this process. TNF is associ
ated With the cellular generation of oxygen free radicals in
tissue and may be one of the primary causes of this condi

TABLE 1

tion. The activation of macrophages and lymphocytes also
60

Testing of antioxidation activity of PBN
control +

Test

sample

PBS

(nM/ml)

% inhibition"

NP132 plasma
NP134 plasma
NP135 plasma

0.55
0.18
0.32

0.45
0.14
0.25

18.2
22.2
21.9
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plays a critical role in the condition. Free radical production
by the White cells is part of the process of multiple organ
damage. Spin-trapping compounds can prevent the propa
gation phase of this condition and limit the extent of
cachexia and organ damage folloWing severe trauma.

Diabetic Retinopathy
Diabetes is a disease of abnormal glycation and partial
ischemia. Both conditions promote free radical production.

US 6,403,627 B1
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The relatively common condition of diabetic retinopathy is
thought to involve a microvascular and protein dysfunction
of the retina. Spin-trapping compounds can limit the glyca
tion mediated production of free radicals and the damage

duction in normal cells. Bleomycin produces pulmonary and
cutaneous toxicities as a result of hydroxyl free radical

production. Adriamycin produces cardiac and gastrointesti
nal side-effects. The spin-trapping compound PBN has been
demonstrated to trap the free radicals produced by adriamy

caused by microvascular interruptions.
Burn Treatment and Healing
Healing from serious burns is limited by the inability of

cin in heart, brain and other organs of research animals,

using the spin-trapping compound PBN. These spin

the repairing vascular system to supply the rapidly groWing

trapping compounds can be used to limit side effects in
tissues, such as the brain and heart, that are especially

cutaneum. Periods of ischemia in the dermis Will occur as

the groWing skin cannot be adequately supplied. This
hypoxia or ischemia results in the production of oxygen free
radicals and either limits the rate of recovery and/or pro
motes the generation of scar tissue. Systemic and topical
spin-trapping compounds can be used to improve the rate of
healing and decrease scar formation.
Ischemic BoWel Disease
Strangulation of the boWel is a condition that is frequently
fatal in both humans and animals such as dogs, horses and
cattle. Even after resection and anastomosis of the intestine,

10

vulnerable to develop free radicals, Without compromising
the therapeutic value of the chemotherapeutic agent.
Skin, Muscle Flap and Organ Survival FolloWing Trans

plantation
Autologous (self) transplantation of skeletal muscles from
15 one area to another should not involve any immunologic

incompatibilities. HoWever, estimates from one surgeon
suggest that the success rate is more in the area of 50%

the prognosis is not good. The generation of ischemia

success. Acceptance of skin ?ap grafts has an equally loW
success rate. It is postulated that much of the problem arises
as a result of ischemia and reperfusion during the surgical

derived oxygen radicals and damage to the intestine is

procedures for removal and implantation. FolloWing

considered to be a primary cause. There is no effective
treatment to date.

ischemia these tissues undergo calcium loading and even
tually necrosis, as in strokes. Spin-trapping compounds can
be used to limit the damage undergone by these tissues, as

Studies have demonstrated that ischemia induced intesti
nal edema can be prevented or reduced by a number of 25 Well as other organs, during surgery associated With trans

plantation.

different spin-trapping compounds.

Organs for transplantation are obtained from donors. The
success of the procedure is determined in part by the age
(oxidation) related reduction in organ viability, the amount
of time the organ is in preservation solution, and the status
of the recipient. Previous research has demonstrated that

Endotoxin is a primary factor in the pathophysiology of

equine gastrointestinal disorders and gram negative bacterial
infections. The pathophysiological is similar to that charac

teriZing colitis, salmonellosis, and neonatal septicemia. It is
hypothesiZed that endotoxin produces its toxic effects by
triggering “oxidative bursts” from sensitiZed macrophages.

spin-trapping compounds can improve the enZymatic status
of the aged brain, restoring enZymatic levels to near those of

These bursts of O2 radicals are intended to kill invading
bacteria associated With the presence of endotoxin.

HoWever, they have the adverse effect of damaging the
tissues in Which they are produced and this tissue damage is
presumably the molecular basis of the pathological changes
associated With endotoxin shock. Spin-trapping compounds
have the ability to trap radicals and alleviate many of the
toxic effects associated With radical formation. Additionally,
recent experiments demonstrate that spin trap molecules
protect rats against endotoxin administration.
Wound and Ulcer Healing
Tissue healing often involves periods of hypoxia or
ischemia as the recovering tissue outgroWs the vascular

35

the young adult as early as seven days folloWing initiation of
daily treatment With a spin-trapping agent such as PBN.

Organ preservation solutions are designed to prepare the
organ to be transplanted for the period of extracorporeal
storage. The most recently developed solution contains
glutathione as an antioxidant. Spin-trapping compounds
differ from glutathione in that they can function both as
antioxidants, trapping oxygen free radicals, as Well as trap

ping compounds for both intracellular and extracellular
carbon-centered free radicals.
It is believed organ survival Would therefore be enhanced
45

supply. Spin-trapping compounds can decrease the damage

by administering spin-trapping compounds to the recipient,
as Well as adding the compounds to the organ preservation
solution.

associated With this period of ischemia.
Infections as consequence of the development of decubi
tus ulcers is the number one cause of death in the elderly.

IoniZing Radiation Prophylaxis.

The general clinical impression is that elderly patients are
much more likely to develop these ulcers, compared to

environmental toxicant causes its effects by producing

young adults. Pressure sores develop as a result of the

Ultraviolet radiation acts similarly. The cascade that folloWs
is functionally identical to the process of cellular damage

interruption of blood How to the skin. This process is
identical to the process of ischemia/reperfusion oxidation of
brain and other tissues. In the geriatric and/or diabetic
patient, pressure sores may develop due to enhanced oxida
tion of the cells of the skin. Based upon the observations that

IoniZing radiation as a therapeutic modality and as an

hydroxyl free radicals intracellularly and extracellularly.
caused by ischemia/reperfusion injury to tissue. Spin
55

trapping compounds can be used to selectively treat those
tissues that are not involved by the cancer, thereby increas

ing the effectiveness of the therapy and decreasing the side

spin-trapping compounds can prevent ischemia/reperfusion
injury to both brain and intestine, it is expected that spin

effects of radiation therapies. In the case of environmental

trapping compounds Will reduce or prevent pressure sores.
In addition, these compounds can be used systemically or

both as a prophylaxis, applied topically or systemically, as
Well as a post-exposure therapeutic.

topically in enhancing recovery.

Treatment of Renal Hypertension Disorders, Resulting from
LoW Renal Artery FloW and High Renin

Reduction in Side-effects of Cancer Chemotherapy
A number of cancer chemotherapeutic agents produce
their cytotoxic effects via the production of oxygen free
radicals Within the cell. The limiting side effects of these
compounds are also the result of oxygen free radical pro

exposures, spin-trapping compounds should be effective

Renal hypertension develops as a result of reduced blood
65

How to the kidney. The juxtaglomerular apparatus (JGA)
recogniZes this hypoperfusion and releases renin, Which
results in an angiotensin II mediated increase in blood
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pressure (hypertension). Hypoperfusion (hypoxia) is a con
dition that is known to result in signi?cant oxygen free

ment of the person administering or supervising the admin
istration of the compositions, and that the concentration

radical production, making it probable that oxygen free

ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

radicals are likely to be involved in the release of renin by

the JGA, and therefore manageable at least in part through

composition. The active ingredient may be administered at

administration of spin-trapping compounds.

once, or may be divided into a number of smaller doses to

Exertional Injury to Skeletal Muscle

be administered at varying intervals of time.

Sore muscles as a result of exercise are thought to be a

Exemplary dosages of the parent phenyl t-butyl nitrone

consequence of free radical mediated peroxidation of skel
etal muscle proteins and lipids. Since chronic treatment With

administered intravenously range from 0.1 to 10 mg/kg of
body Weight in animals. The effective dosage of PBN in
humans for treating age and ischemic related disorders is

10

spin-trapping compounds decreases cellular oxidations and
protects enZymes from oxidative inactivation, daily treat
15

expected to be betWeen approximately 1 and 10 mg/70 kg
body Weight. Toxicity tests have demonstrated that PBN is
completely innocuous, With such loW toxicity that it Was not
possible to determine an LDSO. It is possible to extrapolate

20

What the effective dosage for these compounds Will be.
Since the trapping of endogenous free radicals is speci?c
for only those cells that have been exposed to the conditions
that result in the. production of free radicals, the traps have

ment can be used to improve the process of exercise con

ditioning (especially in the horse). Moreover, aged skeletal
muscle is likely to contain constituents, as do most other
cells in the body. Since Work has demonstrated that chronic
administration of the spin-trapping compound PBN can

from comparative tests using other spin trapping compounds

return cells to the status of a young adult, spin-trapping can
be used to improve the functional status and exercise con

dition of skeletal muscle in aged individuals.

Epistaxis (Pulmonary Bleeding in Horses) and Laminitis

little or no effect on normal cells. The bene?cial effects

Epistaxis (ES) and laminitis are both thought to involve
ischemia/reperfusion injury to the alveolar basement mem
brane and the lamina propria of the hoof, respectively. Since
both of these conditions involve the process of reperfusion
generation of free radicals, spin-trapping compounds can be
used in the prevention, management of treatment of these

occur only in injured cells, and do not require the presence

of speci?c receptors, speci?c enZymes, and/or speci?c cell
types.
25

The spin trapping compound is preferably administered
systemically, most preferably intravenously or orally, since

conditions.

Pharmaceutical Compositions
The spin trapping compounds are administered topically,

these are the most rapid and efficient means for delivering
30

locally, or systemically, depending on the application. When

the active compound to the site of free radical generation.
The spin trapping compound may be administered at once,
or may be divided into a number of smaller doses to be

administered systemically, the compound is preferably
administered orally or intravenously, in an appropriate phar

administered at varying intervals of time. Other methods of

maceutical carrier such as saline or phosphate buffered

saline (PBS) or in tablet form. For topical application, the

Methods of Administration of PBN
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compound is preferably administered in an ointment or
cream base, or by means of a transdermal patch. The

systemic administration can also be used, including inhala
tion or insuf?ation, subcutaneous, intravenous, and intrap
eritoneal administration. The spin trapping compound can
also be administered topically, in an ointment, creme, or

transdermal patch.
The spin trapping composition can be provided in the

compound can also be administered by controlled delivery
devices, such as biodegradable polymers, or by inhalation,

form of a pharmaceutically acceptable salt. As used herein,

insuf?ation or nasal spray. Suitable carriers are knoWn to 40 the term pharmaceutically acceptable salts or complexes

those skilled in the pharmaceutical area.

refers to salts or complexes of that retain the desired

Effective dosages of Spin Trapping Compounds

biological activity of the parent compound and exhibit
minimal, if any, undesired toxicological effects. Nonlimiting

A typical dose of the spin trapping agent for all of the

examples of such salts are (a) acid addition salts formed With

above-mentioned conditions is in the range from about 0.1

to 100 mg/kg, preferably 0.5 to 50 mg/kg, of body Weight
per day. The effective dosage range of the pharmaceutically

45

inorganic acids (for example, hydrochloric acid, hydrobro
mic acid, sulfuric acid, phosphoric acid, nitric acid, and the
like), and salts formed With organic acids such as acetic acid,
oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic

acceptable derivatives can be calculated based on the Weight

of the parent spin trapping compound to be delivered. If the
derivative exhibits activity. in itself, the effective dosage can

acid, benZoic acid, tannic acid, pamoic acid, alginic acid,

be estimated as above using the Weight of the derivative, or
by other means knoWn to those skilled in the art.

polyglutamic acid, naphthalenesulfonic acids, naphthalene

The compound is conveniently administered in any suit
able unit dosage form, including but not limited to one

tion salts formed With polyvalent metal cations such as Zinc,

containing 5 to 2000 mg, preferably 50 to 1500 mg of active

cobalt, nickel, cadmium, sodium, potassium, and the like, or

ingredient per unit dosage form. A oral dosage of 50—1000
mg is usually convenient.
Ideally the active ingredient should be administered to
achieve peak plasma concentrations of the active compound
of from about 0.5 to 100 mM, preferably about 1 to 30 mM.
The concentration of active compound in the drug com

disulfonic acids, and polygalacturonic acid; (b) base addi

calcium, bismuth, barium, magnesium, aluminum, copper,
55
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With an organic cation formed from N,N-dibenZylethylene
diamine, ammonium, or ethylenediamine; or combinations
of (a) and (b); e.g., a Zinc tannate salt or the like.
A preferred mode of administration of the active com
pound is in a form for oral delivery. Oral compositions Will
generally include an inert diluent or an edible carrier.

position Will depend on absorption, inactivation, and excre

Preferred pharmaceutical carriers for intravenous adminis

tion rates of the drug as Well as other factors knoWn to those

tration are saline or phosphate buffered saline at physiologi

of skill in the art. It is to be noted that dosage values Will also
vary With the severity of the condition to be alleviated. It is
to be further understood that for any particular subject,

cal pH. Since some compounds are pH sensitive, stability of
the compound in the carrier should be determined and the

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg
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pH of the carrier adjusted appropriately, or the compound
administered in combination With food, a buffering agent, or

in an enteric coating. For oral delivery, the spin trapping

US 6,403,627 B1
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compound may be enclosed in capsules, compressed into
tablets, microencapsulated, entrapped in liposomes, in solu
tion or suspension,alone or in combination With a substrate

immobilizing material such as starch or poorly absorbable
salts such as immodium. Pharmaceutically compatible bind
ing agents can be included as part of the composition. The
tablets or capsules may contain, for example, any of the
following ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel©, or corn starch; a
lubricant such as magnesium stearate or Sterotes; a glidant
such as colloidal silicon dioxide; a sWeetening agent such as

With the proviso that
(a) both X and Y do not simultaneously represent

sucrose or saccharin; or a ?avoring agent such as

peppermint, methyl salicylate, or orange ?avoring. When

R2

10

15

the dosage unit form is a capsule, it can contain, in addition
to material of the above type, a liquid carrier. In addition,
dosage unit forms can contain various other materials Which

Wherein n is 1 to 5 and Wherein R2 is halogen, alkyl,

NHZ, —S(alkyl), haloalkyl, or
In

modify the physical form of the dosage unit, for example,
coatings of sugar, shellac, or other enteric agents.
Modi?cations and variations of the spin trapping compo
sitions for the treatment of a variety of disorders associated

Where Z is a C1_6 straight or branched chain alkyl;
and
(b) Where Y is phenyl, then X does not represent

With oxidation of proteins and/or lipids Will be obvious to
those skilled in the art from the foregoing detailed descrip
tion. Such modi?cations and variations are intended to come 25

Within the scope of the appended claims.

S

We claim:
1. Amethod for the treatment of dysfunctions and disease

conditions arising from oxidative damage comprising
administering to a patient in need of such treatment an
effective amount of a compound of the formula

Where n is 1 to 5 and Wherein R2 is halogen or alkyl.
2. The method of claim 1 Wherein the disorder is of the
central and peripheral nervous system and disorders of the

peripheral organs.
35

Wherein:
X is imidaZolyl, phenothiaZinyl or

3. The method of claim 2 Wherein the disorder is a
disorder of a peripheral organ.
4. The method of claim 3 Wherein said peripheral organ is
the skin.
5. The method of claim 1 Wherein the disorder is selected

from the group consisting of stroke, Parkinsonism,
concussion, aneurysm, ventricular hemorrhage and associ
ated vasospasm, migraine and other vascular headaches,
spinal cord trauma, diabetic retinopathy and neuroanesthesia

R2

adjunct.
6. The method of claim 1 Wherein the disorder is selected

from the group consisting of diabetic peripheral neuropathy
45

and traumatic nerve damage.
7. The method of claim 1 Wherein the disorder is selected

from the group consisting of atherosclerosis, chronic

R2=independently (can vary Within the molecule)

obstructive pulmonary disease, pancreatitis, pulmonary

halogen, alkyl, alkenyl, oxyalkenyl, NHZ, NHZ, NZ2,

?brosis due to chemotherapeutic agents, angioplasty, burns,

NO,

ischemic boWel disease, ulcers and bed sores, lupus, ulcer
ative colitis, organ transplantation, renal hypertension, over
exertion of skeletal muscle and epistaxis.
8. The method of claim 1 Wherein the disorder is the result
of exposure to cytotoxic compounds and radiation selected
from the group consisting of X-ray, ultraviolet, gamma or
beta radiation.
9. The method of claim 8 Wherein the radiation is ultra
violet radiation.
10. The method of claim 1 Wherein said compound is
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administered topically.
11. The method of claim 10 Wherein said compound is

—S(alkenyl), and haloalkyl;

administered in conjunction With an ointment or cream base

suitable for topical administration.
12. The method of claim 1 Wherein said compound is
administered in conjunction With a pharmaceutically accept

A=O or S; and

Z is a C1 to C6 straight or branched alkyl or cyclic group;
and
Y is a tert-butyl group that can be hydroxylated or
acetylated at one or more positions; phenyl or

65

able carrier.
13. The method of claim 1 Wherein said compound is
administered in a pharmaceutically acceptable carrier
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17. The method of claim 1, Wherein X is irnidaZolyl.
18. The method of claim 1, Wherein X is phenothiaZinyl.

selected from the group consisting of carriers for intrave
nous administration, oral adrninistration, adrninistration via

the respiratory tract, subcutaneous adrninistration, intrarnus
cular adrninistration, rectal administration and topical

19. The method of claim 1 Wherein X is

administration.
14. The method of claim 1, Wherein Y is a tert-butyl group
that can be hydroXylated or acetylated.

15. The method of claim 1, Wherein Y is phenyl.
16. The method of claim 1, Wherein Y is
10

CH

R2

20. The method of claim 1 Wherein Z is alkyl.
*

*

*
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